Limited Time Offer! Save up to $6,000 per device with re:Vive 2.0

Studies, News and More

Published Studies

Introducing Heru

November 9, 2021 – Heru

Heru Fills The Need For Greater Access To Care

November 9, 2021 – Heru

Rethinking Glaucoma Management Using Wearable Diagnostics From Heru
re:Vive™ Visual Field

July 25, 2021 – Heru

Rethinking Glaucoma Management
Heru’s Advancements Of Visual Field Testing For Glaucoma

July 30, 2021 – Heru

Press Releases

Heru Transforms the Future of Eye Care with the Release of re:Vive 2.0: A Single Wearable Platform with 6 Vision Diagnostic Modalities that Support 5 CPT Codes

November 9, 2021

Study Shows Heru’s Automated Visual Field Testing Platform Delivers Strong Correlation to Humphrey Field Analyzer

September 22, 2021

Heru, the Wearable Diagnostic and Vision Augmentation Leader, Launches Commercial Availability of re:Vive in Partnership with Vision Source

August 5, 2021

Heru, the Wearable Diagnostic and Vision Augmentation Leader, Bolsters Executive Team with Seasoned Industry Veterans

July 13, 2021

In the News

Heru registers AI vision test with FDA, begins commercialization pilot

December 28, 2020 – BioWorld

Medical technology company Heru, Inc completes FDA registration following a $2.7M seed round

December 22, 2020 – Ophthalmology360

Cloud-based augmented/virtual reality platform receives class I listing with FDA

December 21, 2020 – Ophthalmology Times

Be the first to know

Receive product updates and get early access to Heru technologies.